Results 131 to 140 of about 1,165,642 (310)

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola   +5 more
wiley   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar   +6 more
wiley   +1 more source

A recent history of disease outbreaks in Kenya, 2007–2022: Findings from routine surveillance data

open access: yesBMC Research Notes
Background Africa reports the highest number of outbreaks globally, accounting for 39% of all outbreaks in 2022. The Integrated Disease Surveillance and Response strategy in Kenya ensures the reporting of outbreaks up to the national level.
Farida Geteri   +5 more
doaj   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster   +10 more
wiley   +1 more source

Report on the epidemiology of tuberculosis in Ireland 2005 [PDF]

open access: yes, 2007
In Ireland, national epidemiological data on TB have been collated by the Health Protection Surveillance Centre (HPSC) since 1998. From January 2000, this information has included enhanced surveillance data items based on the minimum dataset reported ...
Hickey, Lorraine   +4 more
core  

When meta‐analyses mislead: Promises and pitfalls in teratology counselling

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Meta‐analysis has become a central tool for evidence synthesis in clinical teratology, offering the promise of increased statistical power, earlier signal detection and consolidated guidance for teratology counselling. When conducted rigorously and interpreted carefully, pooled analyses can provide clinicians with a structured basis for risk ...
Yusuf Cem Kaplan, Nusret Uysal
wiley   +1 more source

Weekly report on the epidemiology of COVID-19 in Ireland Week 6, 2024

open access: yes
Report produced by the Health Protection Surveillance Centre. The epidemiological weeks in this report, run from Sunday to Saturday. Please refer to the HPSC website for a complete list of epidemiological weeks with start and end dates for 2020 ...
Health Protection Surveillance Centre (HPSC)
core   +1 more source

Unsupervised machine learning for multi‐system adverse event pattern detection in pharmacovigilance: A proof‐of‐concept analysis of fluoroquinolone reports in FAERS

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
. Aims Traditional pharmacovigilance detects single drug–event associations but cannot readily characterize multi‐system adverse‐event patterns such as fluoroquinolone‐associated disability. We evaluated unsupervised machine learning for this purpose, using fluoroquinolones as an exemplar.
Niaz Chalabianloo   +3 more
wiley   +1 more source

Triangulation of dispensing and wastewater data for surveillance during lisdexamfetamine shortages: A descriptive time series analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Lisdexamfetamine, a long‐acting stimulant for attention‐deficit hyperactivity disorder (ADHD), has experienced widespread shortages in Australia since late 2023, raising concerns about treatment continuity and shifts in stimulant use patterns.
Jack Janetzki   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy